Related by context. All words. (Click for frequent words.) 76 % asthenia malaise 72 myalgia arthralgia 71 fatigue asthenia 69 patients receiving ERBITUX 69 Dermatologic toxicities 69 peripheral sensory neuropathy 69 pyrexia mucositis sepsis febrile 69 lopinavir r arm 69 neutropenia dehydration dyspnea 69 hypophosphatemia 69 leucopenia 68 experienced hypomagnesemia 68 neutropenia thrombocytopenia 67 lymphopenia 67 stomatitis 67 leukopenia 67 mcg kg REBETOL 66 REYATAZ r arm 66 PREZISTA r arm 66 generalized edema 66 receiving INTRON 66 Hypomagnesemia occurred 65 FluCAM arm 65 TEAEs 65 â ‰ ¥ 65 pyrexia 65 sensory neuropathy 65 laboratory abnormalities 64 mcg BID 64 receiving PEGINTRON 64 incidence ≥ 64 hematologic toxicity 64 oxycodone CR 64 neutropenia anemia 64 achieved ACR# 63 ALT flares 63 unresectable HCC 63 dizziness nausea diarrhea 63 hematologic adverse 63 Infusion Reactions Severe 63 headache nasopharyngitis 63 paresthesias 63 radiation dermatitis 63 receiving VICTRELIS 63 mcg QD 63 infliximab monotherapy 62 anemia leukopenia 62 del 5q MDS 62 abdominal pain flatulence 62 diarrhea nausea vomiting 62 PROCTOCORT ® Suppository Hydrocortisone 62 thrombocytopenia anemia 62 mucositis 62 arthralgia 62 headache abdominal pain 62 mg BID 62 metabolic alkalosis 62 angioneurotic edema 62 % AST SGOT 62 nasopharyngitis 62 superficial edema 62 adjunctive placebo 62 mucositis stomatitis 62 neutropaenia 61 peripheral edema 61 receiving XGEVA 61 adverse reactions occurring 61 achieved PASI 61 8mg/kg 61 ertapenem 61 severe hypomagnesemia 61 Acetate Rectal Suppositories 61 ALT elevations 61 ALT elevation 61 HBeAg negative patients 61 thrombocytopenia neutropenia 61 conjunctival hyperemia 61 mucosal inflammation 61 events AEs 61 % CI #.#-#.# [003] 61 Viread Emtriva Sustiva 61 placebo dexamethasone 61 REMICADE monotherapy 61 hypokalemia 61 dysesthesia 61 Peg IFN 61 piotr.skolimowski @ thomson.com 61 events SAEs 61 non hematological toxicities 61 constipation nausea 61 hypomagnesemia 61 patients evaluable 61 % CI #.#-#.# [007] 60 metastatic GIST 60 treatment emergent adverse 60 headache nausea fatigue 60 severe exacerbations 60 Cream USP 1 60 discontinuations due 60 mcg albinterferon alfa 2b 60 transaminase elevations 60 brand ciclesonide HFA 60 mg TID 60 adjunctive ABILIFY 60 receiving ISENTRESS 60 anemia neutropenia 60 diarrhea vomiting nausea 60 MCyR 60 events TEAEs 60 ug dose 60 neutropenia febrile neutropenia 60 events thrombocytopenia neutropenia 60 Stomatitis 60 nausea dizziness vomiting 60 thrombocytopenia 60 dermatologic toxicities 60 salmeterol fluticasone 60 febrile neutropenia 60 Adverse events 60 mucocutaneous reactions 60 mg qd 60 dysuria 60 anaphylactoid reactions 60 MADRS score 60 linaclotide treated 60 somnolence dizziness 59 hypopituitarism 59 alfa 2a 59 #mg BID [003] 59 adefovir treated 59 refractory NSCLC 59 prednisone prednisolone 59 4mg/kg 59 Neutropenia 59 Psoriasis Area 59 PREZISTA r 59 & s2 = 59 chlorambucil 59 alpha interferons 59 gastrointestinal toxicities 59 aminotransferase elevations greater 59 Severe acneform rash 59 CR CRu 59 x ULN 59 mg ustekinumab 59 ribavirin therapy 59 FOLFOX4 alone 59 highly emetogenic 59 Lactic acidosis 59 patrick.graham @ thomson.com 59 mU liter 59 partial remissions 59 plus aztreonam 59 relapsed MM 59 Acneform rash occurred 59 hematological toxicities 59 microgram kg 59 nonfatal MI 59 #mg BID [001] 59 confidence interval #.#-#.# 59 Renal impairment 59 pruritis 59 moderate renal impairment 59 nasopharyngitis headache 59 HBeAg seroconversion 59 severe hypersensitivity reactions 59 NMIBC 59 morphometric vertebral fractures 59 dexamethasone Decadron 59 bone marrow suppression 58 plus dexamethasone 58 external genital lesions 58 #mg/m# [001] 58 cytogenetic response 58 arterial thromboembolic events 58 neuropathy sensory 58 benazepril 58 doxorubicin cyclophosphamide 58 APTIVUS r 58 fatal pulmonary embolism 58 evaluable subjects 58 mg m² 58 mg eq 58 severe neutropenia 58 hemorrhagic cystitis 58 hematological adverse 58 5-FU/LV 58 ® fluocinonide Cream 58 kBq kg 58 mg BID dose 58 Serious adverse reactions 58 COPD exacerbation 58 myelosuppression 58 receiving VELCADE 58 Kidney toxicity nephrotoxicity 58 TYSABRI treated 58 Mg Usa 58 daunorubicin 58 HBeAg positive 58 diarrhea dyspepsia 58 plus methotrexate 58 % CI #.#-#.# [006] 58 Hypersensitivity reactions 58 abdominal distention 58 pancytopenia 58 X ULN 58 neutropenic sepsis 58 fatal anaphylactic 58 mg q#h 58 ≥ 58 pawel.sobczak @ thomson.com 58 hypoglycemic events 58 Erythropoietic therapies may 58 comparator arm 58 diarrhea headache nausea 58 Flu Cy 58 mg QD 58 BUPHENYL 58 plus gemcitabine 58 adrian.krajewski @ thomson.com 58 oral levofloxacin 58 HBeAg 58 NovoLog ® Mix 57 AEs 57 aspartate aminotransferase AST 57 alanine aminotransferase 57 Infusion reactions 57 Discontinuations due 57 TMC# r 57 certolizumab 57 elevated ALT 57 umol L 57 Peginterferon Alfa 2a 57 neutropenia 57 stage IIIb IV 57 recurrent VTE 57 g trans fats 57 anaphylactic reactions bronchospasm 57 adriamycin 57 stomatitis pharyngitis 57 DLTs 57 LOANS BY CATEGORY 57 aspartate aminotransferase 57 HBeAg positive patients 57 % #NY.INST 57 TMP SMX 57 ps :# 57 SGPT 57 recurrent DVT 57 undergone splenectomy 57 Network Uptime Money 57 q#h 57 HBeAg negative 57 #mg q8h 57 plus GP IIb 57 trimethoprim sulfamethoxazole 57 headache nausea diarrhea 57 salmeterol HFA MDI 57 anemia hemoglobin 57 ribavirin RBV 57 OS = ISD/#/#/# 57 Xeloda monotherapy 57 prednisone prednisolone plus 57 Avg Hourly % 57 budesonide pMDI 57 Partial Responses 57 elevated serum creatinine 57 dermatologic reactions 57 nonhematologic adverse reactions 57 AND PREMIUMS 57 Postoperative complications 57 pruritus 57 severe renal impairment 57 Soyabean Ext Bulk 57 hip BMD 57 carboplatin paclitaxel 57 rizatriptan 57 normal ULN 57 Peripheral edema 57 lopinavir r 56 p = NS 56 virologic breakthrough 56 microg 56 ARCALYST ® 56 extrapyramidal symptoms 56 palmar plantar 56 CrCl 56 Mg Uk 56 #R #R #R [002] 56 % Confidence Interval 56 nicardipine 56 achieved CCyR 56 telaprevir dosed 56 Stainless Rod 56 Hycamtin ® 56 DETROL LA 56 WEEK ENDING INDEX 56 microbiological eradication 56 amoxicillin clavulanate 56 nadolol 56 renal insufficiency 56 CANCIDAS 56 tolterodine ER 56 undetectable HBV DNA 56 ACTEMRA TM 56 advanced adenomas 56 transaminase 56 mitoxantrone plus 56 receiving Vectibix monotherapy 56 deep venous thromboses 56 ALT normalization 56 delayed CINV 56 Treatment emergent adverse 56 MIC# [001] 56 PREZISTA ritonavir 56 limiting toxicity 56 acute bipolar mania 56 #.#mg/dL 56 receiving prophylactic anticoagulation 56 CCyR 56 Suppository Hydrocortisone Acetate Rectal 56 FOLFOX4 56 metformin monotherapy 56 #mg/day [001] 56 tumor lysis syndrome 56 Off Magazines 56 nodular partial response 56 μg doses 56 recurrent venous thromboembolism 56 annualized relapse 56 dapagliflozin plus 56 tapentadol ER 56 abacavir lamivudine 56 fluticasone salmeterol 56 aplastic anemia AA 56 kg m² 56 nucleoside naive 56 lamivudine refractory patients 56 Discontinuations 56 somnolence sedation 56 #mg QD [002] 56 CI #.#-#.# [001] 56 gastrointestinal perforation 56 NNT = 56 rectal tenesmus 56 mg tid 56 melphalan prednisone 56 events MACE 56 ug kg 56 log# copies mL 56 adverse reactions ≥ 56 SGOT 56 chronic urticaria 56 erythema redness 56 hepatic dysfunction 56 Islands Sportfishing 55 CHANGE WEEKLY CHANGE 55 isoproterenol 55 Febrile neutropenia 55 CI #.#-#.# [002] 55 interferon alfa 2a 55 mEq 55 mso footer margin 55 biochemical relapse 55 confidence interval CI 55 INCOME TAX EFFECTS 55 3mg/kg 55 NUMBER OF TRADERS 55 PASI scores 55 FOLFIRI 55 prior chemotherapy regimens 55 mild renal insufficiency 55 infusion reactions 55 FOLFOX6 55 photosensitivity rash 55 log# reduction 55 - -Books Market Segmentation 55 -#.# log# 55 incontinence episodes 55 BARACLUDE ® 55 syncopal 55 lamivudine monotherapy 55 virological failure 55 nonfatal stroke 55 Thrombotic events 55 asthma exacerbation 55 seroconverted 55 mg/m2/day 55 dysmenorrhoea 55 nmol l 55 insomnia somnolence 55 nephrotoxic 55 nadroparin 55 saline placebo 55 CIMZIA TM certolizumab pegol 55 WEIGHTED AVG 55 Hypotension 55 Adverse reactions 55 Psychopharmacology Berl 55 aged ≥ 55 EDSS scores 55 Besivance TM 55 haematologic 55 reinfarction 55 locoregional recurrence 55 elevated transaminases 55 thromboembolic events 55 lumbar spine bone 55 flutamide 55 % mlink 55 KRAS mutations occur 55 CR nPR 55 posaconazole 55 hematologic toxicities 55 KRAS mutant tumors 55 mL/min/#.# m 2 55 azoospermia 55 mcg mL 55 quetiapine risperidone 55 endometrial hyperplasia 55 moderately emetogenic 55 OTHER NET 55 IRLS score 55 http:/events.fai.org 55 Soriatane R acitretin capsules 55 colorectal adenoma 55 evaluable 55 chemotherapy induced neutropenia 55 pts RESEARCH 55 progressive PsA 55 versus +9 55 doxazosin 55 mso header 55 malignancy HCM 55 lymphocytosis 55 glycated hemoglobin levels 55 achieved sustained virologic 55 corticosteroid therapy 55 VIIBRYD 55 non splenectomized 55 mg + GLY 54 Index CDAI 54 plus glycoprotein IIb 54 dizziness somnolence 54 achieving PASI 54 Hand eczema 54 Nebulized 54 glipizide plus 54 hallucinations dyskinesia 54 log# IU mL 54 peginterferon alfa 2a 54 tipranavir r 54 oral olanzapine 54 pmol L 54 hypocalcemia 54 ‰ ¥ 54 TAXUS p value 54 q#d 54 hypercalcemia 54 oral allopurinol 54 mg/# h 54 BUPHENYL R sodium phenylbutyrate 54 splenectomized 54 Asymptomatic 54 Nephrol Dial Transplant 54 #.#g/day 54 recurrent glioblastoma multiforme 54 peginterferon alfa 2b 54 electrolyte abnormalities 54 cytopenias 54 Apidra ® 54 achieved mucosal healing 54 cGy 54 hematologic abnormalities 54 FOLFIRI alone 54 Fasting blood glucose 54 LPV r 54 Dermatologic Toxicity Dermatologic toxicities 54 peginterferon alfa 54 hepatorenal syndrome 54 arterial thromboembolic 54 plus MTX 54 evaluable patients 54 hepatic failure 54 PegIFN RBV 54 intravenous bisphosphonates 54 binary restenosis 54 alanine aminotransferase ALT 54 HBeAg + 54 sotalol 54 Treatment discontinuations due 54 mg Proellex 54 μg dose 54 definite stent thrombosis 54 rFSH 54 Q2W 54 ATACAND 54 symptomatic BPH 54 CIN2 + 54 TNF antagonist 54 enamel defects 54 neutropenic patients 54 splenectomized patients 54 classes #A# #A# 54 neutrophil counts 54 VFEND 54 mild renal impairment 54 receiving highly emetogenic 54 Biaxin clarithromycin 54 thrombosis embolism 54 hypercholesterolaemia 54 Vertebral fractures 54 OF NET CAPITALIZATION 54 liver decompensation 54 piperacillin tazobactam 54 rash pruritus nausea 54 QTc prolongation 54 Seroquel quetiapine fumarate 54 PegIFN 54 advanced adenoma 54 baseline serum creatinine 54 cerebrovascular accidents 54 SAN DIEGO Helgren Oceanside 54 neutropenic fever 54 hemorrhagic complications 54 oral diclofenac 54 statin monotherapy 54 -#.# mg dL [002] 54 hypoglycaemic episodes 54 interferon alfa 2b 54 metformin accumulation 54 BY RALPH SAO 54 jana.mlcochova @ thomson.com 54 P = .# 54 mcg linaclotide 54 Margo Quatrino 54 serum IGF 54 neck receiving ERBITUX 54 % CI #.#-#.# [008] 54 PLX STROKE targeting 54 hypersensitivity reactions 54 p = .# [001] 54 micrograms mL 54 severe hypoglycemic 54 PRADAXA #mg 54 Hepatic Impairment 54 hematological toxicity 54 β blocker 54 hemodynamically significant 54 nondiabetic patients 54 LEXIVA r 54 oral prednisolone 54 RLAI 54 mL sec 53 mcg kg 53 BSE SMALLCAP index 53 headache arthralgia 53 unknown etiology 53 #mg/day [002] 53 caspofungin 53 intravitreal injections 53 lispro 53 mL/min/#.# m2 53 lumbar spine BMD 53 refractory gout 53 #mg #mg #mg [003] 53 desvenlafaxine succinate 53 acromegalic patients 53 mg d 53 thromboembolic 53 thrombophlebitis 53 liver histology 53 mg dosed twice 53 comorbid ADHD 53 extrapyramidal symptoms EPS 53 RGT arm 53 Exclusion criteria 53 Folfox 53 #.#/#.# mmHg [001] 53 fulminant hepatitis 53 lactic acidosis 53 pegylated interferon alfa 2b 53 BENICAR 53 • dcastell@visalia.gannett.com • 53 serum aminotransferase levels 53 bleeding ulceration 53 creatinine clearance 53 calculated creatinine clearance 53 NR CC 53 venous thromboembolic events 53 sUA 53 #.#/#.# mm Hg [003] 53 solifenacin 53 related hematological toxicity 53 NNRTI resistance 53 μg mL 53 generalized tonic clonic seizures 53 amenorrhea 53 J Am Podiatr 53 #μg [001] 53 CHD CVD 53 ceftazidime 53 % CI #.#-#.# [005] 53 lung esophageal 53 ng dL 53 symptomatic hyponatremia 53 Pharmacokinetic parameters 53 heparin induced thrombocytopenia 53 mU L 53 Pred Forte 53 QT interval prolongation 53 hepatic metastases 53 naïve HCV 53 pamidronate 53 nephrotoxicity 53 #Gy 53 Tumor shrinkage 53 MISSOURI TOTAL 53 ACR Pedi 53 nausea diarrhea 53 plus prednisone 53 intra articular injection 53 prolonged QT interval 53 g carbo 53 IU ml 53 postmenopausal osteoporotic women 53 pimecrolimus cream 53 vaccinees 53 salmeterol fluticasone propionate 53 onset diabetes mellitus 53 composite endpoint 53 MBq 53 prolonged cytopenias 53 venlafaxine XR 53 fluorouracil leucovorin 53 ddI 53 Eur Respir J 53 HBsAg positive 53 dalteparin 53 permanently discontinue Vectibix 53 gout flare 53 n = 53 parous women 53 EGYPTIAN POUND 53 % CI #.#-#.# [004] 53 dacarbazine 53 #.#mg/kg [002] 53 beclomethasone dipropionate 53 hepatotoxicity 53 Hypocalcemia 53 CHESS Depository Interests CDIs 53 ischemia driven 53 atazanavir ritonavir 53 ritonavir boosted 53 Nonperforming Assets NPAs 53 genotypic resistance 53 triiodothyronine 53 intracranial hemorrhage ICH 53 neurologic complications 53 CDAI score 53 anaphylactic symptoms 53 clodronate 53 HGPIN 53 mEq L 53 HF hospitalization 53 thromboembolic complications 53 HMG CoA reductase inhibitors 53 mg administered orally 53 genotype 1b 52 Skin rashes 52 pooled comparator 52 detrusor overactivity 52 HAM D# scores 52 nonsignificant difference 52 Thal Dex 52 μg kg 52 steroid dexamethasone 52 ARCALYST ® rilonacept 52 remission induction 52 dyspnea 52 hepatic enzymes 52 mg kg dose 52 cEVR 52 mIU ml 52 HIV uninfected 52 vertebral fracture 52 hyperkalemia 52 Homes Sold tbr 52 ARB telmisartan 52 underwent surgical resection 52 fractional shortening 52 Anaphylactic reactions 52 R LAV 52 treatment naïve genotype 52 ipsilateral breast 52 OCEANSIDE Helgren 52 % miconazole nitrate 52 MACCE 52 ECOG PS 52 noise THD + 52 pegylated liposomal doxorubicin 52 symptomatic hypotension 52 OADs 52 Australia # DIVCO 52 titrated glipizide 52 iniparib BSI 52 + - Vulnerable 52 mCi m 2 52 hepatic enzyme 52 pheochromocytoma 52 baseline FEV 52 plus ribavirin 52 % CI #.#-#.# [002] 52 -#.# ± [002] 52 ug ml 52 overt nephropathy 52 stage IIIB 52 aminotransferases 52 nonsevere disability 52 Planetwide Media My 52 hours postdose 52 potentially hepatotoxic 52 mg kg ip 52 Eur Arch 52 intravenous bolus 52 nausea constipation 52 Secondary endpoints 52 mg orally 52 papillary renal cell carcinoma 52 systemic corticosteroids 52 CIN3 52 Noninterest expense decreased 52 octreotide LAR 52 peg IFN 52 discontinuations 52 p = .# [002] 52 cerebrovascular events 52 R# #mg BID 52 CRESTOR #mg 52 symptomatic pulmonary embolism 52 ropivacaine 52 BMI ≥ 52 Nonperforming loans totaled 52 virologic failure 52 Known hypersensitivity 52 multivariate adjustment 52 Index CDAI score 52 didanosine associated 52 CIMZIA TM 52 ìg 52 Crohn Disease Activity 52 Primary endpoints 52 undergone radical prostatectomy 52 remission CR 52 anaphylaxis angioedema 52 Lantus ® 52 low dose cytarabine 52 TOTAL REV 52 estramustine 52 EXJADE 52 REYATAZ ritonavir 52 HbA 1c levels 52 Exacerbations 52 ABC/3TC 52 Tardive dyskinesia 52 Ann Oncol 52 underwent CABG 52 #.#.# ordinary 52 #mmHg [001] 52 + PH# 52 mmHg systolic 52 -#.# ± [001] 52 perioperatively 52 specific alkaline phosphatase 52 -#.# mg dL [001] 52 unfractionated heparin UFH 52 symptomatic VTE 52 HPV-#/# 52 SIERRA LEONE MEDIA 52 CDAI 52 Oral mucositis 52 uM 52 nausea vomiting constipation 52 mmHg diastolic 52 experienced virologic failure 52 Operative mortality 52 thrombocytopenic 52 renal toxicity 52 squamous histology 52 μg d 52 metastatic carcinoid tumors 52 pneumonitis 52 aprepitant 52 IIIa inhibitors 52 pericardial effusion 52 myocardial infarction stroke 52 pT3 52 HeFH 52 resuscitated cardiac arrest 52 n Cooling Degree 52 jason.hovet @ thomsonreuters.com 52 lenalidomide dexamethasone 52 serum phosphorous 52 β blockers 52 IIIa inhibitor 52 #mg/m# [002] 52 myopathy rhabdomyolysis 52 HPA axis suppression 52 CI -#.# 52 EQUITAS NOMINEES PTY 52 TAXOTERE ® 52 OPERATING EXPENSES SELLING EXPENSES 51 Thrombocytopenia 51 candesartan cilexetil 51 idiopathic PD 51 reduce serum phosphate 51 REBETOL therapy 51 retrograde ejaculation 51 International Liftboats 51 AML MDS 51 Leasable area 51 serum HCV RNA 51 GERD symptom 51 placebo PBO 51 weekly CSBMs 51 extrapyramidal side 51 iodixanol 51 corticosteroid dose 51 NPH insulin 51 Allergic reactions 51 mg Androxal 51 fluorouracil 51 1mg dose 51 PSA nadir 51 CLL SLL 51 AVODART 51 IMPOSED ON 51 Ulla Paajanen Sainio VP 51 transaminases 51 DAS# remission 51 Secondary endpoints included 51 5FU 51 mg p = 51 QTcF 51 akathisia 51 Am J Cardiol 51 unstable angina pectoris 51 postoperative AF 51 ocular adverse 51 recurrent ischemia 51 spinal cord compression 51 paclitaxel carboplatin 51 DJI #.# 51 TOTAL OFFENSIVE PLAYS . 51 syncope fainting 51 protein excretion 51 EFFEXOR XR 51 LANTUS R 51 #mg dose [002] 51 mitoxantrone 51 fasting triglyceride levels 51 distant metastasis 51 TOTAL OPERATING INCOME 51 Ishak fibrosis score 51 mg simvastatin 51 mg/m2 dose 51 CK # plasma concentrations 51 impaired renal 51 AVONEX multiple sclerosis 51 ARCOXIA 51 Available Seat Kilometres ASKs 51 CC genotype 51 INVEGA ® 51 intraocular inflammation 51 revascularizations 51 μmol L 51 torsade de pointes 51 confidence intervals CIs 51 vinorelbine 51 cytologically confirmed 51 potassium sparing diuretics 51 de novo AML 51 bacteriuria 51 angioedema 51 irbesartan 51 HOW WOULD YOU FEEL 51 univariate analysis 51 tibiofemoral 51 macroalbuminuria 51 eplerenone 51 histologically proven 51 pg mL 51 Hb A1C 51 subtrochanteric 51 FOLFOX 51 #mg doses [002] 51 Severe hypoglycemia 51 elevated LDH 51 Marfrig BMF & 51 antiretroviral naïve 51 Fitch Affirms SLM 51 R LANV CC 51 Solid Tumors criteria 51 nmol 51 mmol l 51 tertile 51 mm Hg diastolic 51 anaphylactic reactions 51 apolipoprotein B 51 tirofiban 51 coinfected patients 51 mg/m2 administered 51 mol L 51 tipranavir ritonavir 51 mg/m2 IV 51 metabolic acidosis 51 adefovir 51 mCi 51 vitreous haze 51 nM 51 ipsilateral stroke 51 #.#-#.# [011] 51 Eur J Pharmacol 51 Posaconazole 51 mg XP# 51 glucuronide 51 ug mL 51 intravenous RSD# 51 FORWARD LOOKING INFORMATION WITHIN 51 gemifloxacin 51 chronic HCV genotype 51 baseline HbA1c 51 REBETOL 51 plus medroxyprogesterone acetate 51 nonmetastatic 51 SSRI SNRI 51 PEG IFN 51 primidone 51 serum leptin 51 angiotensin converting enzyme inhibitor 51 REYATAZ r 51 clinically evaluable patients 51 REMICADE ® 51 hyperprolactinemia 51 Eur J Endocrinol 51 endoscopic remission 51 hypersensitivity reaction 51 radiotherapy RT 51 Foreclosed Assets 51 TT genotype 51 balsalazide 51 detectable HCV RNA 51 cholecystitis 51 RELEASE ACCORDING TO 51 oral prednisone 51 mCi kg 50 PROVE TO BE 50 - -KITCHENER ONTARIO Marketwire 50 Rating Scale MADRS 50 hypertension pulmonary arterial 50 isoprostane 50 ACR# response 50 dopaminergic therapy 50 fasting plasma glucose FPG 50 Kidney Int 50 null responder HCV 50 hormone receptor negative 50 #μg [002] 50 mmol liter 50 FROVA 50 hypervolemic 50 atorvastatin #mg 50 thromboembolism 50 nonvertebral fracture 50 #ng/ml 50 intramuscularly 50 Median PFS 50 DMARD therapy 50 mg RDEA# 50 complete cytogenetic response 50 pCR 50 pulmonary exacerbations 50 Yr -# 50 placebo p 50 efavirenz EFV 50 GEMZAR 50 homozygotes 50 Hematologic 50 exacerbations 50 rFVIIa 50 CHOP chemotherapy 50 neurologic progression 50 -pass code SHOPNBC 50 parecoxib 50 dizziness constipation 50 Hum Mol Genet 50 AM EDT POSITION 50 mcg dL 50 kg -1